Celldex Therapeutics (CLDX) Total Debt (2010 - 2013)

Celldex Therapeutics' Total Debt history runs 4 years deep, the most recent figure standing at $15.7 million for Q1 2013.

• On a quarterly basis, Total Debt rose 3.6% year-over-year to $15.7 million in Q1 2013; TTM through Mar 2013 was $15.7 million, a 3.6% increase from a year earlier, with the FY2012 full-year figure at $11.3 million, down 25.13% from the prior year.
• Total Debt climbed to $15.7 million in Q1 2013 per CLDX's latest filing, from $11.3 million in the prior quarter.
• Across five years, Total Debt topped out at $19.2 million in Q2 2012 and bottomed at $10.0 million in Q4 2010.
• The 4-year median for Total Debt is $15.1 million (2011), against an average of $14.4 million.
• Across the five-year window, Total Debt soared 51.44% in 2011 and declined 25.13% in 2012, its largest moves.
• Year by year, Total Debt stood at $10.0 million in 2010, then surged by 51.44% to $15.1 million in 2011, then slipped by 25.13% to $11.3 million in 2012, then surged by 38.74% to $15.7 million in 2013.
• Per Business Quant, the three latest CLDX Total Debt figures stand at $15.7 million (Q1 2013), $11.3 million (Q4 2012), and $12.6 million (Q3 2012).